Luc BUEE PhD Neurobiology

Course and current status

Luc Buée is a French scientist (CNRS Research Director), Director of the Lille Neuroscience & Cognition Research Centre and Head of the Inserm laboratory « Alzheimer & Tauopathies » at the University of Lille, France. His group is also part of the laboratory of Excellence (LabEx) DISTALZ and the Centre of Excellence in Neurodegenerative disorders (LiCEND).

He is currently the president of the French Society for Neurosciences.

Luc Buée has a background in biochemistry, cell biology and neurosciences.

From 1989 to 1992, he prepared a PhD in the department of Geriatrics, Mount Sinai Medical Center, New York, USA under the supervision of Professor Howard Fillit and André Delacourte (Inserm, France), on “the role of proteoglycans in amyloidosis in Alzheimer's disease". He graduated from the University of Lille in October 1992

From 1992 to 1994, he was a post-doctoral fellow (funded by France Alzheimer Association) in the Inserm laboratory headed by Marc Mazzuca in Lille.

In October 1994, he has been appointed Research Associate by the CNRS (the French National Centre for scientific research). Since then, he has worked on Alzheimer disease and related disorders. He was  involved in the initial characterization of tau aggregates among neurodegenerative disorders. He has then developed experimental models to better understand the role of post-translational modifications in tau aggregation and tau secretion.

Since 2001, he is CNRS research director and heads a Inserm team dedicated to the understanding of neurodegenerative disorders and neuronal death on the hospital (CHU) campus at the University of Lille. Since 2020, he leads the research centre "Lille Neuroscience & Cognition"

Scientific summary

1)      Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, Skrobala E, Landrieu I, Michel A, Schmitt M, Citron M, Downey P, Courade JP, Buée L*, Colin M* (2019) Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain, 142(6):1736-1750

2)      Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP, Buée L. Exploring anti-tau immunotherapy within the hypothesis of the prion-like propagation. Acta Neuropathol, in press

3)      Corvol JC, Buée L (2019) A new step towards targeting tau. Lancet Neurol, 18:517-8.

4)      Domise M, Sauvé F, Didier S, Caillerez R, Bégard S, Carrier S, Colin M, Marinangeli C, Buee L, Vingtdeux V (2019) Neuronal AMP-activated protein kinase (AMPK) hyper-activation induces synaptic loss by an autophagy mediated process. Cell Death Dis, 10:221

5)      Dupré E, Danis C, Arrial A, Cantrelle FX, Merzougui H, Hanoulle X, Colin M, Rain JC, Buée L*, Landrieu I* (2019) Single chain antibody fragments as new tools for studying the neuronal Tau protein physiopathology. ACS Chemical Neurosci, 10(9):3997-4006

6)      Fichou Y, Al-Hilaly YK, François Devred F, Smet-Nocca C Tsvetkov PO, Verelst J, Winderickx J, Geukens N, Vanmechelen E, Perrotin A, Serpell L, Hanseeuw B, Medina M, Buée L*, Landrieu I* (2019) The elusive Tau Molecular structures: Can we translate the recent breakthroughs into new targets for intervention? Acta Neuropathol Commun, 7:31

7)      Houben S, Leroy K, Ando K, Yilmaz Z, Widomski C, Buée L, Brion JP (2019) Genetic ablation of tau in postnatal neurons rescues decreased adult hippocampal neurogenesis in a tauopathy model. Neurobiol Dis, 127:131-141

8)      Jadhav S, Avila J, Schöll M, Kovacs G, Kövari E, Skrabana R, Evans L, Kontsekova E, Malawska B, de Silva R, Buée L*, Zilka N* (2019) A walk through tau therapeutic strategies. Acta Neuropathol Commun, 7: 22.

9)      Leboucher A, Ahmed T, Caron E, Tailleux A, Raison S, Joly Amado A, Marciniak E, Carvalho K, Hamdane M, Bantubungi K, Lancel S, Eddarkaoui S, Caillierez R, Vallez E, Staels B, Vieau D, Balschun D, Buée L*, Blum D* (2019) Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiol Dis, 125 :14-22.

10)   Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte A, Giusti P, Zusso M, Robert P, Frisoni G, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B (2019) Current and emerging avenues for Alzheimer’s disease drug targets. J Intern Med, 286(4):398-437

11)   Paiva I, Carvalho K, Cellai L, Santos P, Pavlou MAS, Jain G, Gnad T, Pfeifer A, Vieau D, Fischer A, Buée L, Outeiro TF, Blum D (2019) A2AR-induced transcriptional deregulation in astrocytes: an in vitro study. Glia, 67(12):2329-2342

12)   Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Le Fur N, Evrard C, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Hamdane M, Buee L, Melnyk P (2019) New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer’s disease. Neurobiol Dis, 129: 217-33.

13)   Dujardin S, Lachaud C, Caillierez R, Bégard S, Carrier S, Lieger S, Gonzales JA, Moore BD, Deramecourt V, Deglon N, Maurage CA, Frosch MP, Hyman BT, Colin M, Buée L (2018)  Different Tau species lead to heterogeneous Tau pathology propagation and misfolding. Acta Neuropathol Commun, 6:132

14)   Gratuze M, Joly-Amado A, Vieau D, Buée L, Blum D (2018) Mutual relationship between Tau and central insulin signalling: consequences for AD and Tauopathies ? Neuroendocrinology, 107: 181-95.

15)   Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Tréluyer JM, Gelé P, Delmaire C, Blanc F, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe–Gillot L, Paccalin M, Robert PH, Godefroy O, Dantoine T, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen S*, Gabelle* on behalf of the BALTAZAR study group (2018) Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers. Alzheimers & Dementia, 14:858-68.

16)   Laurent C, Buée L, Blum D (2018) Tau and neuroinflammation: what impact for Alzheimer’s disease and Tauopathies. Biomed J, 41: 21-33

17)   Sierksma A, Lu A, Salta E, Vanden Eynden E, Callaerts-Vegh Z, D'Hooge R, Blum D, Buee L, Fiers M, De Strooper B (2018) Deregulation of neuronal miRNAs induced by either amyloid-β or TAU pathology. Mol Neurogener, 13(1):54.

18)   Dourlen P, Fernandez-Gomez F, Dupont C, Grenier-Boley B, Bellenguez C, Obriot H, Caillierez R, Sottejeau Y, Chapuis J, Bretteville A, Abdelfettah F, Delay C, Malmanche N, Soininen H, Hiltunen M, Galas MC, Amouyel P, Sergeant N, Buée L, Dermaut B, Lambert JC (2017) Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Mol Psychiatr, 22(6):874-883. doi: 10.1038/mp.2016.59.

19)   Huin V, Buée L, Behal H, Labreuche J, Sablonnière B, Dhaenens CM (2017) Alternative promoter usage generates novel shorter MAPT mRNA transcripts in Alzheimer’s disease and progressive supranuclear palsy brains. Sci Rep, 7(1):12589. doi: 10.1038/s41598-017-12955-7

20)   Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, Duong Y, Légeron FP, Leboucher A, Burnouf S, Faivre E, Carvalho K, Caillierez R, Zommer N, Demeyer D, Jouy N, Sazdovitch V, Schraen-Maschke S, Delarasse C, Buée L*, Blum D* (2017) Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of Tauopathy. Brain, 140(Pt 1):184-200. doi: 10.1093/brain/aww270

21)   Lebouvier T, Pasquier F, Buée L (2017) Update on Tauopathies. Curr Op Neurol, 30(6):589-598

22)   Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, Issad T, Gerhardt E, Pagesy P, Vileno M, Bournonville C, Hamdane M, Bantubungi K, Lancel S, Demeyer D, Eddarkaoui S, Vallez E, Vieau D, Humez S, Faivre E, Grenier-Boley B, Outeiro TF, Staels B, Amouyel P, Balschun D, Buee L*, Blum D* (2017) Tau deletion promotes brain insulin resistance. J Exp Med, 214(8):2257-2269. doi: 10.1084/jem.20161731

23)   Mudher A, Brion JP, Avila J, Medina M, Buée L (2017) EuroTau meeting: Towing scientists to Tau without tautology. Acta Neuropathol Commun, 5: 90

24)   Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alvavi Naini SM, Mandelkow EM, Mandelkow E, Buée L, Goedert M, Brion JP (2017) What is the evidence that Tau pathology spreads through a prion-like propagation ? Acta Neuropathol Comm, 5: 99.

25)   Šimić G, Leko MB, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, Silva R, Giovanni GD, Wischik C, Hof PR (2017) Monoaminergic Neuropathology in Alzheimer's disease. Prog Neurobiol, 151 : 101-138.

26)   Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, Blum D, Sayas CL, Mandelkow EM, Mandelkow E, Spillantini MG, Sousa N, Avila J, Medina M, Mudher A, Buee L (2017) Atypical, non-standard functions of the microtubule-associated Tau protein. Acta Neuropathol Comm, 5: 91

27)   Huin V. Deramecourt V, Caparros-Lefebvre D, Maurage CA, Duyckaerts C, Kovari E, Pasquier F, Buée-Scherrer V, Labreuche J, Behal H, Buée L, Dhaenens CM, Sablonnière B (2016) The MAPT gene is differentially methylated in the progressive supranuclear palsy brain. Mov Disord, 31(12):1883-1890. doi: 10.1002/mds.26820.

28)   Kenisberg PA, Aquino JP, Bérard A, Gzil F, Andrieu S, Banerjee S, Brémond F, Buée L, Cohen-Mansfirld J, Mangialasche F, Platel H, Salmon E. Robert P (2016) Dementia beyond 2025: knowledge and uncertainties. Dementia (London), 15(1)6-21. doi: 10.1177/1471301215574785.

29)   Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, Mariciniak E, Parrot S, Van der Jeugd A, Faivre E, Flaten V, Ledent C, D’Hooge R, Sergeant N, Hamdane M, Humez S, Müller CE, Lopes LV, Buée L, Blum D. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatr, 2016, 21(1):97-107.

30)   Papegaey A, Eddarkaoui S, Deramecourt V, Fernandez-Gomez FJ, Pantano P, Obriot H, Machala C, Anquetil V, Camuzat A, Brice A, Maurage CA, Le Ber I, Duyckaerts C, Buée L, Sergeant N, Buée-Scherrer V (2016) Reduced Tau protein expression is associated with frontotemporal dementia with progranulin mutation. Acta Neuropathol Comm, 4(1):74. doi: 10.1186/s40478-016-0345-0.

31)   Tardivel M, Begard S, Bousset L, Dujardin S, Coens A, Melki R, Buée L*, Colin M* (2016) Tunneling nanotube-mediated neuron to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Comm, 4:117 doi: 10.1186/s40478-016-0386-4.

32)   Ahmed T, Blum D, Burnouf S, Demeyer D, Buée-Scherrer V, D’Hooge R, Buée L, Balschun D (2015) Rescue of impaired late-phase LTD in a tau transgenic mouse model. Neurobiol Aging, 36(2) 730-39.

33)   Blum D, Herrera F, Gerhardt E, Francelle L, Basquin M, Obriot H, Sergeant N, Brouillet E, Buée L, Outeiro TF (2015) The impact of Huntingtin mutation on Tau phosphorylation and subcellular distribution. Hum Mol Genet, 24(1):76-85.

34)   Caillet-Boudin ML, Buée L, Sergeant N, Lefebvre B (2015) Regulation of human MAPT gene expression. Mol Neurodegener, 10:28

35)   Caparros-Lefebvre D, Golbe LI, Deramecourt V, Maurage CA, Huin V, Buée-Scherrer V, Obriot H, Sablonnière B, Caparros F, Buée L, Lees AJ (2015) A geographical cluster of progressive supranuclear palsy in Northern France. Neurology, 85(15) 1293-300.

36)   Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez FJ, Laurent C, Demeyer D, Carrier S, Buée-Scherrer V, Blum D, Vinh J, Sergeant N, Verdier Y, Buée L, Hamdane M (2015) Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep, 5:9659

37)   Dujardin S, Colin M, Buée L (2015) Animal models of tauopathies and their implications for research/translation into the clinic. Neuropathol Appl Neurobiol, 41, 59–80

38)   Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T (2015) PART is part of Alzheimer disease. Acta Neuropathol, 129(5):749-56

39)   Frederick C, Ando K, Leroy K, Heraud C, Buée L, Brion JP (2015) Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. J Alzheimers Dis, 44(4):1145-56

40)   Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Mazoyer B, Schraen Maschke S, Buee L, Debette S (2015) Association of plasma amyloid-ß with MRI markers of structural brain aging. Neurobiol Aging, 36(10)2663-70

41)   Melnyk P, Vingtdeux V, Burlet S, Eddarkaoui S, Grosjean ME, Larchanche PE, Hochart G, Sergheraert C, Estrella C, Barrier M, Poix V, Plancq P, Lannoo C, Hamdane M, Delacourte A, Verwaerde P, Buee L, Sergeant N (2015) Chloroquine- and chloroquinoline-derivatives as models for the design of modulators of Amyloid Peptide Precursor metabolism. ACS Chem Neurosci, 6(4):559-69.

42)   Violet M, Chauderlier A, Delattre L, Tardivel M, Sendid Chouala M, Marciniak E, Humez S, Binder L, Kayed R, Lefebvre B, Bonnefoy E, Buée L, Galas MC (2015) Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. Neurobiol Dis 82:540-51.

43)   Caillet-Boudin ML, Fernandez-Gomez FJ, Tran H, Dhaenens CM, Buee L, Sergeant N (2014) Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci 6:57.

44)   Dujardin S, Bégard S, Caillierez R, Lachaud C, Delattre L, Carrier S, Loyens A, Galas MC, Bousset L, Melki R, Auregan G, Hantraye P, Brouillet E, Buée L*, Colin M* (2014) Ectosomes: A new mechanism for non-exosomal secretion of Tau protein. PLoS One, 9(6):e100760.

45)   Dujardin S, Lécolle K, Caillierez R, Bégard S, Zommer N, Lachaud C, Carrier S, Dufour N, Aurégan G, Winderickx J, Hantraye P, Déglon N, Colin M*, Buée L* (2014) Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun 2(1):14.

46)   Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Zhu Y, Crivello F, Maillard P, Schraen Maschke S, Mazoyer B, Buee L, and Debette S (2014) Plasma amyloid-ß and MRI markers of cerebral small vessel disease. Neurology, 83(22):2038-45

47)   Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, Schneider M, Hamdane M, Müller CE, Buée L, Blum D (2014) Beneficial effects of caffeine in a transgenic model of Alzheimer’s Disease-like Tau pathology. Neurobiol Aging, 35(9):2079-90.

48)   Violet M, Delattre L, Tardivel M, Sultan A, Chauderlier A, Caillierez R, Talahari S, Nesslany F, Lefebvre B, Bonnefoy E, Buée L, Galas MC (2014) A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front Cell Neurosci. 2014 Mar 18;8:84.

49)   Ando K, Sambo AV, Dourlen P, Bretteville A, Belarbi K, Vingtdeux V, Eddarkoui S, Drobecq H, Ghestem A, Bégard S, Demey-Thomas E, Melnyk P, Smet C, Lippens G, Maurage CA, Caillet-Boudin ML, Verdier Y, Vinh J, Landrieu I, Galas MC, Blum D, Hamdane M, Sergeant N, Buee L (2013) Pin1 post-translational modifications are modulated by Tau pathology and may be relevant as biomarker. Neurobiol Aging 34(3):757-69.

50)   Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D (2013) NMDA receptor dysfunction contributes to impaired BDNF-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell, 12(1): 11-23.

51)   Caillierez R, Bégard S, Lécolle K, Deramecourt V, Zommer N, Dujardin S, Loyens A, Dufour N, Aurégan G, Winderickx J, Hantraye P, Déglon N, Buée L* and Colin M* (2013) Lentiviral delivery of the human wild-type Tau protein mediates a slow and progressive neurodegenerative Tau pathology in the rat brain. Mol Ther 21(7):1358-68

52)   Chaunu MP, Deramecourt V, Buée-Scherrer V, Le Ber I, Brice A, Ehrle N, El Hachimi K, Pluot M, Maurage CA, Bachkine S, Buée L (2013) Juvenile frontotemporal dementia with parkinsonism associated with Tau mutation G389R. J Alzheimers Dis. 37(4):769-76

53)   Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E, Bantubungi K, Breton C, Pigny P, Buée-Scherrer V, Staels B, Hamdane M, Tailleux A, Buée L, Blum D (2013) Detrimental Effects of Diet-Induced Obesity on τ Pathology Is Independent of Insulin Resistance in τ Transgenic Mice. Diabetes, 62(5):1681-8.

54)   Lécolle K, Bégard S, Caillierez R, Grellier E, Loyens A, Beauvillain JC, D’Halluin JC, Baroncini M, Lejeune JP, Sharif A, Prévot V, Dournaud P, Buée L, Colin M (2013) Somatostatin receptor type 2: a relevant target for the selective delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors. Gene Therapy 20(3): 283-297

55)   Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, De Strooper B, Buée L (2012) Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-ß1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci 32(23):7852–7861

56)   Deramecourt V, Lebert F, Maurage CA, Fernandez-Gomez FJ, Dujardin S, Colin M, Sergeant N, Buée-Scherrer V, Clot F, Le Ber I, Brice A, Pasquier F, Buée L (2012) Clinical, neuropathological and biochemical characterization of the novel Tau mutation P332S. J Alzheimers Dis 31: 741-9

57)   Le Freche H, Brouillette J, Fernandez-Gomez FJ, Patin P, Caillierez R, Zommer N, Sergeant N, Lebuffe G, Blum D, Buée L (2012) Tau phosphorylation and sevoflurane anesthesia: a link to postoperative cognitive impairment. Anesthesiology 116(4):779-787

58)   Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen S, Blum D, Buée L (2012) Targeting phospho-Ser422 by active immunotherapy in the Thy-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9(4): 397-405

59)   Vingtdeux V, Sergeant N, Buee L (2012) Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. Frontiers in Physiology 3: 229   DOI: 10.3389/fphys.2012.00229

60)   Belarbi K, Burnouf S, Fernandez-Gomez F, Desmercieres J, Troquier L, Brouillette J, Tsambou L, Grosjean ME, Caillierez R, Demeyer D, Hamdane M, Schindowski K, Blum D, Buée L (2011) Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology? Curr Alzheimer Res, 8: 633-638.

61)   Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M, Sultan A, Troquier L, Leboucher A, Caillierez R, Grosjean ME, Demeyer D, Obriot H, Brion I, Barbot B, Galas MC, Staels B, Humez S, Sergeant N, Muhr-Tailleux A, Hamdane M, Buee L, Blum D (2011) Beneficial effects of exercise in a transgenic mouse model of Alzheimer’s disease-like Tau pathology. Neurobiol Dis 43:486-94.

62)   Deramecourt V, Maurage CA, Sergeant N, Buée-Scherrer V, Buée L, Defebvre L (2011) An 88-year old woman with a long lasting parkinsonism. Brain Pathol, 21(4) 65-68.

63)   Smith PY, Delay C, Girard J, Papon MA, Planel E, Sergeant N, Buée L, Hébert SS (2011) MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 20(20):4016-24

64)   Sultan A, Nesslany F, Violet M, Bégard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Buée L, Galas MC (2011) Nuclear Tau : a key player in neuronal DNA protection. J Biol Chem, 286(6): 4566-4575

65)   Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME, Humez S, Balschun D, Blum D, Buée L, D'Hooge R (2011) Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem, 95(3) : 296-304

66)   Buée L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, Fernandez-Gomez F, Caillierez R, Grosjean ME, Begard S, Barbot B, Demeyer D, Obriot H, Brion I, Buée-Scherrer V, Maurage CA, Balschun D, D’Hooge R, Hamdane M, Blum D, Sergeant N (2010) From Tau phosphorylation to Tau aggregation: what about neuronal death? Biochem Soc Trans. 38: 967-972.

67)   Hébert SS, Papadopoulou AS, Smith P, Galas MC, Planel E, Silahtaroglu AN, Sergeant N, Buée L, De Strooper B (2010) Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet, 19(20):3959-69.

68)   Belarbi K, Schindowski K, Burnouf S, Caillierez R, Grosjean ME, Demeyer D, Hamdane M, Sergeant N, Blum D, Buee L (2009) Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model : relevance to Alzheimer’s disease. Curr Alzheimer Res, 6(2) 152-157.

69)   Bretteville A, Ando K, Ghestem A, Loyens A, Bégard S, Beauvillain JC, Sergeant N, Hamdane M, Buée L (2009) Two-dimensional electrophoresis of Tau mutants reveals specific phosphorylation pattern likely linked to early Tau conformational changes. PLoS One, 4(3):e4843.

70)   Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alpérovitch A, Buée L, Amouyel P (2009) Association of plasma Ab with risk of dementia: the prospective 3C-study. Neurology, 73 :847-53.

71)   Schindowski K, Belarbi K, Bretteville A, Ando K, Buée L (2008) Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation. Genes Brain Behav, 7: 92-100

72)   Schindowski K, Belarbi K, Buée L (2008) Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav, 7:43-56

73)   Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, Caillet-Boudin ML, Pasquier F, Maurage CA, Sablonnière B, Vanmechelen E, Buée L (2008) Tau as biomarker of neurodegenerative diseases. Biomarkers in Medicine, 2(4): 363-384.

74)   Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S, Buée L (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics, 5(2):207-24.

75)   Dourlen P, Ando K, Hamdane M, Begard S, Buee L, Galas MC. The peptidyl prolyl cis/trans isomerase Pin1 downregulates the inhibitor of apoptosis protein Survivin. Biochem Biophys Acta – Mol Cell Res, 1773(9) : 1428-37.

76)   Hamdane M, Buée L. The complex p25/Cdk5 kinase in neurofibrillary degeneration and neuronal death : the missing link to cell cycle. Biotechnology J, 2(8): 967-77.

77)   Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, Yilmaz Z, Buée L, Brion JP. Early axonopathy preceding neurofibrillary tangles in a mutant tau transgenic mice. Am J Pathol, 171: 976-92.

78)   Vingtdeux V, Hamdane M, Bégard S, Loyens, Delacourte A, Beauvillain JC, Buée L,  Marambaud P, Sergeant N. Intracellular-pH regulates amyloid precursor protein intracellular domain degradation. Neurobiol Dis, 25(3):686-96.

79)   Vingtdeux V, Hamdane M, Loyens, Gele P, Drobeck H, Bégard S, Galas MC, Delacourte A, Beauvillain JC, Buée L, Sergeant N. Alkalizing drugs induce accumulation of amyloid precursor protein byproducts in lumenal vesicles of multivesicular bodies J Biol Chem, 282(25): 18197-205.

80)   Galas MC, Dourlen P, Ando K, Bégard S, Blum D, Hamdane M, Buée L (2006) The peptidylprolyl cis/trans isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. J Biol Chem, 281: 19296-304.

81)   Hamdane M, Dourlen P, Bretteville A, Sambo AV, Ferreira S, Ando K, Kerdraon O, Bégard S, Geay L, Sergeant N, Delacourte A, Lippens G, Maurage CA, Galas MC, Buee L. Pin1 allows for differential Tau dephosphorylation in neuronal cells. Mol Cell Neurosci, 32: 155-160.

82)   Schindowski K, Bretteville A, Leroy K, Bégard S, Brion JP, Hamdane M, Buée L (2006) Alzheimer disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol, 169(2) 599-616.

83)   Delobel P, Leroy O, Hamdane M, Sambo AV, Delacourte A, Buee L. Proteasome inhibition and Tau proteolysis: an unexpected regulation. FEBS Lett 579(1): 1-5.

84)   Hamdane M, Bretteville A, Sambo AV, Schindowski K, Bégard S, Delacourte A, Bertrand P, Buée L. Retinoblastoma phosphorylation is an early step in p25/Cdk5-induced neuronal cell death. J Cell Sci 118:1291-98.

85)   Sergeant N, Delacourte A, Buée L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta – Mol Biol Dis, 1739(2-3): 179-97.

86)   Hamdane M, Sambo AV, Delobel P, Bégard S, Violleau A, Delacourte A, Bertrand P, Benavides J, Buee L. Mitotic-like Tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem. 278: 34026-34.

87)   Delobel P, Flament S, Hamdane M, Mailliot C, Sambo AV, Begard S, Sergeant N, Delacourte A, Vilain JP, Buée L. Abnormal Tau phosphorylation of the Alzheimer type also occurs during mitosis. J Neurochem, 83: 412-420.

88)   Delobel P, Flament S, Hamdane M, Delacourte A, Vilain JP, Buée L. Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3ß and pKA kinase activities. FEBS Lett, 516: 151-155.

89)   Delobel P, Flament S , Hamdane M, Jakes R, Rousseau A, Delacourte A, Vilain JP, Goedert M, Buée L (2002) Effects of FTDP-17 tau mutations during Xenopus laevis oocyte meiosis. J Biol Chem, 277: 9199-9205.

90)   Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau isoforms in neurodegenerative disorders. Brain Res Rev 33 : 95-130.

91)   Mailliot C, Podevin-Dimster V, Rosenthal RE, Sergeant N, Delacourte A, Fiskum G, Buée L. Rapid tau protein dephosphorylation and differential rephosphorylation during cardiac arrest-induced cerebral ischemia and reperfusion. J Cereb Blood Flow Metab, 20: 543-549.

92)   Buée L, Delacourte A (1999) Comparative biochemistry of tau proteins among neurodegenerative disorders. Brain Pathology, 9 : 681-693.

93)   Bussière T, Hof PR, Mailliot C, Brown C, Caillet-Boudin ML, Perl DP, Buée L, Delacourte A. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol, 97: 221-230.

94)   Mailliot C, Sergeant N, Bussière T, Caillet-Boudin ML, Delacourte A, Buée L (1998) Phosphorylation of specific sets of tau isoforms explains different neurodegeneration processes. FEBS Lett, 433: 201-204.

95)   Mailliot C, Bussière T, Caillet-Boudin ML, Delacourte A, Buée L (1998) Alzheimer-specific epitope of AT100 in transfected cell lines with tau: Toward an efficient cell model of tau abnormal phosphorylation. Neurosci Lett, 255: 13-16.

96)   Buée L, Hof PR, Delacourte A (1997) Brain microvascular changes in Alzheimer’s disease and other dementias. In Cerebrovascular pathology in Alzheimer’s disease. Ann NY Acad Sci 826 : 7-24.

97)   Delacourte A., Buée L (1997) Normal and pathological tau proteins as factors for microtubule assembly. Int Rev Cytol, 171: 167-224.

98)   Buée L, Pérez-Tur J, Leveugle B, Buée-Scherrer V, Loerzel A, Chartier-Harlin M-C, Perl DP, Delacourte A, Hof PR (1996) Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: genotype analysis and relationships to neuropathologic changes. Acta Neuropathol, 91: 247-253.

99)   Buée L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH, Fillit HM (1994) Pathologic alterations of the cerebral microvasculature in Alzheimer's disease and related disorders. Acta Neuropathol, 87: 469-480.

100) Buée L, Ding W, Delacourte A, Fillit H (1993) Binding of secreted human neuroblastoma proteoglycans to the Alzheimer amyloid A4 peptide. Brain Res, 601: 154-163.

101) Buée L, Ding W, Anderson JP, Narindrasorasak S, Kisilevsky R, Boyle NJ, Robakis NK, Delacourte A, Greenberg B, Fillit HM (1993) Binding of vascular heparan sulfate proteoglycan to the Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide. Brain Res, 627: 199-204.

102) Buée L, Hof PR, Roberts DD, Delacourte A, Morrison JH, Fillit HM (1992) Immunohistochemical identifica-tion of Thrombospondin in normal human brain and Alzheimer's disease. Am J Pathol, 141: 783-788.

103) Buée L, Boyle N, Zhang L, Delacourte A, Fillit H (1991) Optimization of an Alcian blue dot-blot assay for the detection of glycosaminoglycans and proteoglycans. Anal Biochem, 195: 238-242.

104) Buée L, Laine A, Delacourte A, Flament S, Han KK (1991) Qualitative and quantitative comparison of brain proteins in Alzheimer's disease. Biol Chem Hoppe-Seyler, 370: 1229-1234.

Image d’exemple